Treatment of Kawasaki disease: Analysis of 27 US Pediatric Hospitals from 2001 to 2006

Pediatrics

Volumn 124, Issue 1, 2009, Pages 1-8

  Son, Mary Beth F ^a,b   Gauvreau, Kimberlee ^a,b   Ma, Lin ^a,b   Baker, Annette L ^a,b   Sundel, Robert P ^a,b   Fulton, David R ^a,b   Newburger, Jane W ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Coronary artery aneurysm; Infliximab; Kawasaki disease

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; HEPARIN; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; PREDNISONE; PROPRANOLOL; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ADOLESCENT; ADULT; ANTICOAGULANT THERAPY; ARTICLE; CHILD; CORONARY ARTERY ANEURYSM; DATA ANALYSIS; DRUG USE; FEMALE; HIGH RISK PATIENT; HISPANIC; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATIENT CODING; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALIZATION; HOSPITALS, PEDIATRIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFANT, NEWBORN; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; UNITED STATES; YOUNG ADULT;

EID: 67649623214     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-0730     Document Type: Article

References (31)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [in Japanese]. Arerugi. 1967;16(3):178-222
2. Burns JC, Kushner HI, Bastian JF, et al. Kawasaki disease: a brief history. Pediatrics. 2000;106(2). Available at: www.pediatrics.org/cgi/content/ full/106/2/e27
3. Melish ME, Hicks RM, Larson EJ. Mucocutaneous lymph node syndrome in the United States. Am J Dis Child. 1976;130(6):599-607 (Pubitemid 8000903)
4. Belay ED, Maddox RA, Holman RC, Curns AT, Ballah K, Schonberger LB. Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994-2003. Pediatr Infect Dis J. 2006;25(3):245-249
5. Chang RK. Epidemiologic characteristics of children hospitalized for Kawasaki disease in California. Pediatr Infect Dis J. 2002;21(12):1150-1155 (Pubitemid 35463033)
6. Chang RK. Hospitalizations for Kawasaki disease among children in the United States, 1988-1997. Pediatrics. 2002;109(6). Available at: www.pediatrics.org/cgi/content/full/109/6/e87
7. Chang RK. The incidence of Kawasaki disease in the United States did not increase between 1988 and 1997. Pediatrics. 2003;111(5):1124-1125
8. Davis RL, Waller PL, Mueller BA, Dykewicz CA, Schonberger LB. Kawasaki syndrome in Washington State: race-specific incidence rates and residential proximity to water. Arch Pediatr Adolesc Med. 1995;149(1):66-69
9. Dean AG, Melish ME, Hicks R, Palumbo NE. An epidemic of Kawasaki syndrome in Hawaii. J Pediatr. 1982;100(4):552-557
10. Gibbons RV, Parashar UD, Holman RC, et al. An evaluation of hospitalizations for Kawasaki syndrome in Georgia. Arch Pediatr Adolesc Med. 2002;156(5):492-496 (Pubitemid 34492583)
11. Holman RC, Belay ED, Clarke MJ, Kaufman SF, Schonberger LB. Kawasaki syndrome among American Indian and Alaska Native children, 1980 through 1995. Pediatr Infect Dis J. 1999;18(5):451-455
12. Holman RC, Belay ED, Curns AT, Schonberger LB, Steiner C. Kawasaki syndrome hospitalizations among children in the United States, 1988-1997. Pediatrics. 2003;111(2):448
13. Holman RC, Curns AT, Belay ED, et al. Kawasaki syndrome in Hawaii. Pediatr Infect Dis J. 2005;24(5):429-433 (Pubitemid 40664238)
14. Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics. 2003;112(3):495-501
15. Holman RC, Shahriari A, Effler PV, Belay ED, Schonberger LB. Kawasaki syndrome hospitalizations among children in Hawaii and Connecticut. Arch Pediatr Adolesc Med. 2000;154(8):804-808 (Pubitemid 30636628)
16. Rauch AM, Kaplan SL, Nihill MR, Pappas PG, Hurwitz ES, Schonberger LB. Kawasaki syndrome clusters in Harris County, Texas, and eastern North Carolina: a high endemic rate and a new environmental risk factor. Am J Dis Child. 1988;142(4):441-444 (Pubitemid 18104422)
17. Shulman ST, McAuley JB, Pachman LM, Miller ML, Ruschhaupt DG. Risk of coronary abnormalities due to Kawasaki disease in urban area with small Asian population. Am J Dis Child. 1987;141(4):420-425 (Pubitemid 17044831)
18. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous γ-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J. 1998;17(12):1144-1148 (Pubitemid 29023891)
19. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol. 2003;24(2):145-148 (Pubitemid 36920035)
20. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics. 2000;105(6). Available at: www.pediatrics.org/cgi/content/full/105/6/e78
21. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology. 2005;115(1):1-20 (Pubitemid 40598088)
22. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-γ in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol. 1990;56(1):29-36 (Pubitemid 20220882)
23. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146(5):662-667 (Pubitemid 40616253)
24. O'Connor MJ, Saulsbury FT. Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab. Clin Pediatr (Phila). 2007;46(4):345-348 (Pubitemid 46609103)
25. Stenbøg EV, Windelborg B, Hørlyck A, Herlin T. The effect of TNF α blockade in complicated, refractory Kawasaki disease. Scand J Rheumatol. 2006;35(4):318-321 (Pubitemid 44181186)
26. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol. 2004;31(4):808-810 (Pubitemid 38451274)
27. Zulian F, Zanon G, Martini G, Mescoli G, Milanesi O. Efficacy of infliximab in long-lasting refractory Kawasaki disease. Clin Exp Rheumatol. 2006;24(4):453 (Pubitemid 44363551)
28. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132(3):863-873 (Pubitemid 46454266)
29. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis. 2007;13(4):424-430 (Pubitemid 46668247)
30. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis. 2007;13(8):1024-1030 (Pubitemid 47309975)
31. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114(6):1708-1733 (Pubitemid 41754943)